FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2120128360> ?p ?o ?g. }

• W2120128360 abstract "The targeted delivery of cancer therapeutics represents an ongoing challenge in the field of drug development. TRAIL is a promising cancer drug but its activity profile could benefit from a cancer-selective delivery mechanism, which would reduce potential side effects and increase treatment efficiencies. We recently developed the novel TRAIL-based drug platform TR3, a genetically fused trimer with the capacity for further molecular modifications such as the addition of tumor-directed targeting moieties. MUC16 (CA125) is a well characterized biomarker in several human malignancies including ovarian, pancreatic and breast cancer. Mesothelin is known to interact with MUC16 with high affinity. In order to deliver TR3 selectively to MUC16-expressing cancers, we investigated the possibility of targeted TR3 delivery employing the high affinity mesothelin/MUC16 ligand/receptor interaction. Using genetic engineering, we designed the novel cancer drug Meso-TR3, a fusion protein between native mesothelin and TR3. The recombinant proteins were produced with mammalian HEK293T cells. Meso-TR3 was characterized for binding selectivity and killing efficacy against MUC16-positive cancer cells and controls that lack MUC16 expression. Drug efficacy experiments were performed in vitro and in vivo employing an intraperitoneal xenograft mouse model of ovarian cancer. Similar to soluble mesothelin itself, the strong MUC16 binding property was retained in the Meso-TR3 fusion protein. The high affinity ligand/receptor interaction was associated with a selective accumulation of the cancer drug on MUC16-expressing cancer targets and directly correlated with increased killing activity in vitro and in a xenograft mouse model of ovarian cancer. The relevance of the mesothelin/MUC16 interaction for attaching Meso-TR3 to the cancer cells was verified by competitive blocking experiments using soluble mesothelin. Mechanistic studies using soluble DR5-Fc and caspase blocking assays confirmed engagement of the extrinsic death receptor pathway. Compared to non-targeted TR3, Meso-TR3 displayed a much reduced killing potency on cells that lack MUC16. Soluble Meso-TR3 targets the cancer biomarker MUC16 in vitro and in vivo. Following attachment to the tumor via surface bound MUC16, Meso-TR3 acquires full activation with superior killing profiles compared to non-targeted TR3, while its bioactivity is substantially reduced on cells that lack the tumor marker. This prodrug phenomenon represents a highly desirable property because it has the potential to enhance cancer killing with fewer side-effects than non-targeted TRAIL-based therapeutics. Thus, further exploration of this novel fusion protein is warranted as a possible therapeutic for patients with MUC16-positive malignancies." @default.
• W2120128360 created "2016-06-24" @default.
• W2120128360 creator A5005340246 @default.
• W2120128360 creator A5013020518 @default.
• W2120128360 creator A5017126625 @default.
• W2120128360 creator A5051752608 @default.
• W2120128360 creator A5053690002 @default.
• W2120128360 creator A5057047604 @default.
• W2120128360 creator A5060050760 @default.
• W2120128360 creator A5062157417 @default.
• W2120128360 creator A5076087889 @default.
• W2120128360 creator A5080722354 @default.
• W2120128360 date "2014-01-21" @default.
• W2120128360 modified "2023-10-03" @default.
• W2120128360 title "Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3" @default.
• W2120128360 cites W1484817497 @default.
• W2120128360 cites W1743434283 @default.
• W2120128360 cites W1964165239 @default.
• W2120128360 cites W1968266954 @default.
• W2120128360 cites W1969876692 @default.
• W2120128360 cites W1975291295 @default.
• W2120128360 cites W1979568379 @default.
• W2120128360 cites W1979639369 @default.
• W2120128360 cites W1980154450 @default.
• W2120128360 cites W1980154709 @default.
• W2120128360 cites W1991268162 @default.
• W2120128360 cites W1992083261 @default.
• W2120128360 cites W1995837838 @default.
• W2120128360 cites W1999627530 @default.
• W2120128360 cites W2019276845 @default.
• W2120128360 cites W2021631435 @default.
• W2120128360 cites W2025314268 @default.
• W2120128360 cites W2041616494 @default.
• W2120128360 cites W2050396069 @default.
• W2120128360 cites W2056217426 @default.
• W2120128360 cites W2078747183 @default.
• W2120128360 cites W2088291142 @default.
• W2120128360 cites W2097716961 @default.
• W2120128360 cites W2098419540 @default.
• W2120128360 cites W2098990873 @default.
• W2120128360 cites W2106284224 @default.
• W2120128360 cites W2128548077 @default.
• W2120128360 cites W2130988210 @default.
• W2120128360 cites W2133221875 @default.
• W2120128360 cites W2146797845 @default.
• W2120128360 cites W2154632002 @default.
• W2120128360 cites W2161633444 @default.
• W2120128360 cites W2165682716 @default.
• W2120128360 cites W2167926335 @default.
• W2120128360 cites W2169157708 @default.
• W2120128360 cites W2171174540 @default.
• W2120128360 cites W2327001242 @default.
• W2120128360 doi "https://doi.org/10.1186/1471-2407-14-35" @default.
• W2120128360 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3903436" @default.
• W2120128360 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24447304" @default.
• W2120128360 hasPublicationYear "2014" @default.
• W2120128360 type Work @default.
• W2120128360 sameAs 2120128360 @default.
• W2120128360 citedByCount "27" @default.
• W2120128360 countsByYear W21201283602014 @default.
• W2120128360 countsByYear W21201283602015 @default.
• W2120128360 countsByYear W21201283602016 @default.
• W2120128360 countsByYear W21201283602017 @default.
• W2120128360 countsByYear W21201283602018 @default.
• W2120128360 countsByYear W21201283602019 @default.
• W2120128360 countsByYear W21201283602020 @default.
• W2120128360 countsByYear W21201283602021 @default.
• W2120128360 countsByYear W21201283602023 @default.
• W2120128360 crossrefType "journal-article" @default.
• W2120128360 hasAuthorship W2120128360A5005340246 @default.
• W2120128360 hasAuthorship W2120128360A5013020518 @default.
• W2120128360 hasAuthorship W2120128360A5017126625 @default.
• W2120128360 hasAuthorship W2120128360A5051752608 @default.
• W2120128360 hasAuthorship W2120128360A5053690002 @default.
• W2120128360 hasAuthorship W2120128360A5057047604 @default.
• W2120128360 hasAuthorship W2120128360A5060050760 @default.
• W2120128360 hasAuthorship W2120128360A5062157417 @default.
• W2120128360 hasAuthorship W2120128360A5076087889 @default.
• W2120128360 hasAuthorship W2120128360A5080722354 @default.
• W2120128360 hasBestOaLocation W21201283601 @default.
• W2120128360 hasConcept C104317684 @default.
• W2120128360 hasConcept C10679952 @default.
• W2120128360 hasConcept C121608353 @default.
• W2120128360 hasConcept C123894998 @default.
• W2120128360 hasConcept C126322002 @default.
• W2120128360 hasConcept C150903083 @default.
• W2120128360 hasConcept C185592680 @default.
• W2120128360 hasConcept C207001950 @default.
• W2120128360 hasConcept C2777045440 @default.
• W2120128360 hasConcept C2780427987 @default.
• W2120128360 hasConcept C40767141 @default.
• W2120128360 hasConcept C502942594 @default.
• W2120128360 hasConcept C55493867 @default.
• W2120128360 hasConcept C71924100 @default.
• W2120128360 hasConcept C86803240 @default.
• W2120128360 hasConcept C96232424 @default.
• W2120128360 hasConceptScore W2120128360C104317684 @default.
• W2120128360 hasConceptScore W2120128360C10679952 @default.
• W2120128360 hasConceptScore W2120128360C121608353 @default.
• W2120128360 hasConceptScore W2120128360C123894998 @default.

• next